BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/22/2024 11:33:24 AM | Browse: 348 | Download: 892
Publication Name World Journal of Hepatology
Manuscript ID 90325
Country India
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Combined hepatocellular cholangiocarcinoma: A clinicopathological update
Manuscript Source Invited Manuscript
All Author List Mukul Vij, Fadl H Veerankutty, Ashwin Rammohan and Mohamed Rela
ORCID
Author(s) ORCID Number
Mukul Vij http://orcid.org/0000-0003-0149-0294
Fadl H Veerankutty http://orcid.org/0000-0003-3167-0405
Ashwin Rammohan http://orcid.org/0000-0001-9528-8892
Mohamed Rela http://orcid.org/0000-0003-4282-4676
Funding Agency and Grant Number
Corresponding Author Fadl H Veerankutty, Visiting Professor, MBBS, MS, Consultant Physician-Scientist, Surgeon, Comprehensive Liver Care Institute, VPS Lakeshore, NH 66, Nettoor, Maradu, Cochin 682040, India. write2drfadl@gmail.com
Key Words Combined hepatocellular-cholangiocarcinoma; Immunotherapy; Nestin; Hepatocellular carcinoma; Cholangiocarcinoma; Liver cancer; Biomarker; Immune checkpoint inhibitors; Pathology; Genomic landscape
Core Tip Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) represents a poorly understood rare primary liver tumor with a gruesome prognosis. Molecular and genetic characterization of this disease is vital for exploring newer treatment modalities to improve the survival of patients afflicted with this rare entity. In this review, we give an account of the recent developments in the pathology, diagnostic approach, and management of cHCC-CCA.
Publish Date 2024-05-22 11:33
Citation

Vij M, Veerankutty FH, Rammohan A, Rela M. Combined hepatocellular cholangiocarcinoma: A clinicopathological update. World J Hepatol 2024; 16(5): 766-775

URL https://www.wjgnet.com/1948-5182/full/v16/i5/766.htm
DOI https://dx.doi.org/10.4254/wjh.v16.i5.766
Full Article (PDF) WJH-16-766-with-cover.pdf